Adage Capital Partners’s Dianthus Therapeutics DNTH Stock Holding History

Adage Capital Partners’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$18M	Buy	185,000 +25,000	+16%	+$2.18M	0.03%	533
2026 Q1	$13.4M	Buy	+160,000	New	+$9.27M	0.02%	609
2025 Q4	–	Sell	-77,000	Closed	-$3.03M	–	936
2025 Q3	$3.03M	Sell	77,000 -108,000	-58%	-$2.76M	﹤0.01%	779
2025 Q2	$3.45M	Sell	185,000 -4,000	-2%	-$75K	0.01%	735
2025 Q1	$3.43M	Buy	189,000 +9,000	+5%	+$198K	0.01%	731
2024 Q4	$3.92M	Buy	+180,000	New	+$4.63M	0.01%	738
2024 Q3	–	Sell	-250,000	Closed	-$6.47M	–	893
2024 Q2	$6.47M	Sell	250,000 -48,000	-16%	-$1.15M	0.01%	680
2024 Q1	$8.94M	Buy	+298,000	New	+$6.48M	0.02%	621
2023 Q1	–	Sell	-54,291	Closed	-$343K	–	937
2022 Q4	$343K	Buy	54,291 +3,125	+6%	+$55.3K	﹤0.01%	869
2022 Q3	$1.15M	Buy	51,166 +7,044	+16%	+$193K	﹤0.01%	885
2022 Q2	$847K	Buy	44,122 +19,879	+82%	+$491K	﹤0.01%	929
2022 Q1	$1.13M	Buy	+24,243	New	+$1.32M	﹤0.01%	931

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Adage Capital Partners's DNTH Position: Q2 2026 in Review

Adage Capital Partners increased its Dianthus Therapeutics (DNTH) stake by 16% in Q2 2026, buying an estimated $2.18M and bringing the position to 185,000 shares worth $18M. The position accounts for 0.03% of the portfolio, ranked #533.

Adage Capital Partners first reported a position in DNTH in Q1 2022 and has held it in 12 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

Adage Capital Partners held 185,000 shares of Dianthus Therapeutics worth $18M as of Q2 2026.
Adage Capital Partners bought 25,000 Dianthus Therapeutics shares in Q2 2026, an estimated $2.18M.
Dianthus Therapeutics made up 0.03% of Adage Capital Partners's portfolio in Q2 2026, its #533 holding.
Adage Capital Partners first reported a position in Dianthus Therapeutics in Q1 2022 and has held it in 12 quarters since.
270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Adage Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.